Boulevard Bio Emerged From Stealth on Wednesday August 12, 2026 With $65 Million in Founding Financing From Deerfield Management, Naming Immune-Reset Pioneer Georg Schett as Co-Founder, and Disclosing a Precision-Immunology Pipeline Anchored by BLVD101, an Internally Discovered Dual BAFF/APRIL-Targeting Bispecific Antibody Designed to Inhibit BAFF and APRIL Cytokines That Promote the Proliferation and Maturation of B Cells That Drive Autoimmune Disorders; Early Phase 1 Healthy Volunteer Data Supports a 12-Week (Quarterly) Dosing Interval for BLVD101 in IgA Nephropathy (IgAN), Extending the IgAN Indication Activity That Trutakna (Iptacopan-Related Factor B Inhibitor) and Fabhalta (Iptacopan Complement Inhibitor) Opened Up Earlier in the Year
Boulevard Bio emerged from stealth on Wednesday August 12, 2026 with $65 million in founding financing from Deerfield Management, naming Georg Schett (one of the pioneers of immune reset in autoimmune disease) as co-founder. The company disclosed a precision-immunology pipeline of three drug candidates anchored by BLVD101, an internally discovered dual BAFF/APRIL-targeting bispecific antibody. Mechanism: BLVD101 is designed to inhibit BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), two cytokines that promote the proliferation, survival, and maturation of B cells that drive autoimmune disorders. By blocking both cytokines simultaneously, BLVD101 aims to limit the abnormal B cell activity that attacks healthy tissue in autoimmune diseases. Early Phase 1 healthy volunteer data supports a 12-week (quarterly) subcutaneous dosing interval for BLVD101 in IgA nephropathy (IgAN), a positive tolerability and pharmacokinetic profile that would compare favorably against monthly-dosing biologics in adjacent indications. The launch extends the IgAN indication activity that Trutakna and Fabhalta opened up earlier in 2026 with their FDA approvals ten days apart in the same indication category, though those two drugs target the complement pathway (factor B, C5) rather than the B-cell BAFF/APRIL axis that BLVD101 addresses.